Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Effiefficacy and safety of allogeneic CD123 CAR-NK cell therapy in Relapsed/Refractory Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

WMWei MuAZA. H. ZhangYZYicheng Zhang

Discussion

Loading...

Member takes

Overview

Clinical outcomes show 80% response rate in patients with R/R acute myeloid leukemia, indicating the promise of CD123 CAR-NK cell therapy.

Key Points

  • Achieved complete response in 60% of R/R acute myeloid leukemia patients, showing significant antitumor activity.
  • Median age of treated patients was 45 years, and median tumor burden was 50.18%.
  • Observational analysis using whole-exome sequencing revealed important immune dynamics post-infusion.
  • High incidence of cytokine release syndrome necessitates careful monitoring and further study on safety.

Cite This Study

Mu et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e474https://doi.org/10.1182/blood-2025-1639
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1PARP1 inhibition sensitizes AML to CD123 CAR-NK cells via immunophenotypic remodeling2025 · 1 citations
  2. 2CAR-NK cell therapy in hematologic malignancies (2019–2025): A systematic review2025 · 4 citations
  3. 3CAR-T cells in hematologic disorders: acute myeloid leukemia - A systematic review of efficacy and safety2025 · 1 citations
  4. 4CLL-1 chimeric antigen receptor T-cells for the treatment of Acute Myeloid Leukemia: A phase 1 clinical trial2025 · 1 citations
  5. 5Umbilical cord blood CD34+ hematopoietic stem cell-derived natural killer cells in Acute Myeloid Leukemia – a phase I clinical study2025